Grifols introduces Niuliva to the market

Grifols has announced that its human anti-hepatitis B immunoglobulin drug Niuliva has become available to several countries in the EU.

It has been approved for the treatment of hepatitis B virus reinfection after liver transplantation, as well as for hepatitis B-induced liver failure during the maintenance phase in non-replicator patients and is an intravenous drug.

Available in both pre-filled syringe or vial form as well as in an optimum pharmaceutical form, the drug is the first intravenous human anti-hepatitis B immunoglobulin to be registered in Spain.

The company expects that it will be approved for use in a wide number of other countries worldwide over the coming months.

Upon revealing the availability of the drug, Grifols highlights that around 350 million people are chronically infected worldwide by Hepatitis B and that the virus is the most frequent cause of chronic liver disease.

Earlier this year Grifols acquired a stake in Cardio3 BioSciences, which enabled it to further its research and development programme.